Skip to content
sellWeak cluster of 210b5-1 plan

Richard William Scalzo sold $35k of DYN

SVP, Head of Finance & Admin. at Dyne Therapeutics, Inc.. 2,488 shares at an average of $13.95, traded Feb 18, 2025, filed Feb 18, 2025.

Warning score
9
Value
$35k
2,488 shares
Holdings after
124,590
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Officer
    +15
  • Trade size
    $35k at market
    +6
  • Share of holdings sold
    Sold 2.0% of holdings
    0
  • Cluster
    2 insiders selling within 14 days
    +8
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

DYNOct 9, 2026 · close 16.64
Since filing Feb 18, 2025: +20.8%SPY +29.8% · excess -9.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000950170-25-022455, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 18, 2025SOpen-market sale
Common Stock10b5-1
-2,488$13.95$35k124,590Feb 18, 2025

Related signals

Other insiders at Dyne Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
32Weak
DYNbuy
Dyne Therapeutics, Inc.
Brian S Posner
director
$40k
2,500 shares
+10%
30Weak
DYNsell 310b5-1
Dyne Therapeutics, Inc.
John Cox
CEO & President
$107k
5,658 shares
-2%
20Weak
DYNsell 310b5-1
Dyne Therapeutics, Inc.
Douglas Kerr
Chief Medical Officer
$116k
5,035 shares
-3%
15Weak
DYNsell 310b5-1
Dyne Therapeutics, Inc.
Johanna Friedl-Naderer
Chief Commercial Officer
$25k
1,085 shares
-1%
35Weak
DYNsell 410b5-1
Dyne Therapeutics, Inc.
Dirk Kersten
director
$2.5M
129,672 shares
-3%
33Weak
DYNbuy
Dyne Therapeutics, Inc.
Brian S Posner
director
$39k
2,000 shares
+17%
40Moderate
DYNsell 410b5-1
Dyne Therapeutics, Inc.
Dirk Kersten
director
$13M
688,788 shares
-13%
35Weak
DYNbuy
Dyne Therapeutics, Inc.
Brian S Posner
director
$45k
3,000 shares
+35%
26Weak
DYNsell 410b5-1
Dyne Therapeutics, Inc.
John Cox
CEO & President
$41k
2,732 shares
-1%
10Weak
DYNsell 410b5-1
Dyne Therapeutics, Inc.
Douglas Kerr
Chief Medical Officer
$13k
904 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Richard William Scalzo sold $35k of DYN | InsiderTell